JP2024517789A - グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用 - Google Patents

グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用 Download PDF

Info

Publication number
JP2024517789A
JP2024517789A JP2023567067A JP2023567067A JP2024517789A JP 2024517789 A JP2024517789 A JP 2024517789A JP 2023567067 A JP2023567067 A JP 2023567067A JP 2023567067 A JP2023567067 A JP 2023567067A JP 2024517789 A JP2024517789 A JP 2024517789A
Authority
JP
Japan
Prior art keywords
substituted
certain embodiments
pharma
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023567067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517789A5 (https=
Inventor
ハント，ケビン
ジェン，ジェンビン
Original Assignee
ヴァンキア バイオ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァンキア バイオ，インコーポレイテッド filed Critical ヴァンキア バイオ，インコーポレイテッド
Publication of JP2024517789A publication Critical patent/JP2024517789A/ja
Publication of JP2024517789A5 publication Critical patent/JP2024517789A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2023567067A 2021-04-30 2022-04-28 グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用 Pending JP2024517789A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163182734P 2021-04-30 2021-04-30
US63/182,734 2021-04-30
PCT/US2022/026676 WO2022232360A1 (en) 2021-04-30 2022-04-28 Small molecule modulators of glucocerebrosidase activity and uses thereof

Publications (2)

Publication Number Publication Date
JP2024517789A true JP2024517789A (ja) 2024-04-23
JP2024517789A5 JP2024517789A5 (https=) 2025-05-08

Family

ID=83848814

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023567067A Pending JP2024517789A (ja) 2021-04-30 2022-04-28 グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用

Country Status (10)

Country Link
US (1) US20240246952A1 (https=)
EP (1) EP4329880A4 (https=)
JP (1) JP2024517789A (https=)
KR (1) KR20240016286A (https=)
CN (1) CN117751114A (https=)
AU (1) AU2022267285A1 (https=)
BR (1) BR112023022567A2 (https=)
CA (1) CA3218510A1 (https=)
MX (1) MX2023012853A (https=)
WO (1) WO2022232360A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025237303A1 (zh) * 2024-05-14 2025-11-20 先声药业有限公司 β-葡萄糖脑苷脂酶变构调节剂、其药物组合物及用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011025690A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
JP2012505898A (ja) * 2008-10-16 2012-03-08 シェーリング コーポレイション ピロリジン、ピペリジンおよびピペラジン誘導体ならびにそれらの使用方法
JP2018525345A (ja) * 2015-07-01 2018-09-06 ノースウェスタン ユニバーシティ 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7488721B2 (en) * 2004-05-13 2009-02-10 Mcmaster University Real time methylumbelliferone-based assay
KR101880411B1 (ko) * 2009-10-19 2018-07-19 아미쿠스 세라퓨틱스, 인코포레이티드 중추신경계의 퇴행성 질환을 예방 및/또는 치료하는 신규 조성물
HK1220325A1 (zh) * 2013-03-15 2017-05-05 Whitehead Institute For Biomedical Research 苯并咪唑衍生物及其用途
US9796680B2 (en) * 2013-12-23 2017-10-24 Alectos Therapeutics Inc. Glucocerebrosidase modulators and uses thereof
WO2019027765A1 (en) * 2017-08-02 2019-02-07 Northwestern University SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF
EP4039685A1 (en) * 2021-02-08 2022-08-10 Irbm S.P.A. Azabicyclic shp2 inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012505898A (ja) * 2008-10-16 2012-03-08 シェーリング コーポレイション ピロリジン、ピペリジンおよびピペラジン誘導体ならびにそれらの使用方法
WO2011025690A1 (en) * 2009-08-27 2011-03-03 Merck Sharp & Dohme Corp. Novel pyrrolidine derived beta 3 adrenergic receptor agonists
JP2018525345A (ja) * 2015-07-01 2018-09-06 ノースウェスタン ユニバーシティ 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY[ONLINE], JPN7026000023, ISSN: 0005770609 *

Also Published As

Publication number Publication date
WO2022232360A1 (en) 2022-11-03
MX2023012853A (es) 2024-01-12
US20240246952A1 (en) 2024-07-25
EP4329880A1 (en) 2024-03-06
BR112023022567A2 (pt) 2024-02-06
AU2022267285A1 (en) 2023-11-09
KR20240016286A (ko) 2024-02-06
CA3218510A1 (en) 2022-11-03
EP4329880A4 (en) 2025-03-05
CN117751114A (zh) 2024-03-22

Similar Documents

Publication Publication Date Title
JP7427812B2 (ja) 血漿カリクレインの阻害剤およびその使用
EP3652329B1 (en) Compounds for tau protein degradation
JP2016531113A (ja) 転写因子の阻害剤およびその使用
JP2024518000A (ja) グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用
KR20250109229A (ko) Ripk2 억제제 및 이의 용도
JP2024529487A (ja) Ｒｏｃｋ２阻害剤およびその使用
US20260055090A1 (en) Oxadiazole hdac6 inhibitors and uses thereof
JP2024517789A (ja) グルコセレブロシダーゼ活性の小分子モジュレータ及びその使用
JP2024539628A (ja) グルコセレブロシダーゼ活性の小分子モジュレーターおよびその使用
HK40123072A (en) Inhibitors of plasma kallikrein and uses thereof
HK40029252B (en) Inhibitors of plasma kallikrein and uses thereof
HK40029252A (en) Inhibitors of plasma kallikrein and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250425

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260413